The effects of dietary supplementation with Agaricales mushrooms and other medicinal fungi on breast cancer: evidence-based medicine by Novaes, Maria Rita Carvalho Garbi et al.
REVIEW
The effects of dietary supplementation with
Agaricales mushrooms and other medicinal fungi on
breast cancer: Evidence-based medicine
Maria Rita Carvalho Garbi Novaes, Fabiana Valadares, Mariana Campos Reis, Daniella Rodrigues
Gonc¸alves, Marilia da Cunha Menezes
Universidade de Brası´lia, School of Medicine, Institute of Health Science (ESCS), Brası´lia/DF, Brazil.
Breast cancer is the most prevalent cancer in women. The most frequent therapeutic approaches for the treatment of
this disease are chemotherapy, radiotherapy, hormone therapy, and surgery. Conventional pharmacological treatments
cause many harmful side effects in patients. To improve the quality of life of breast cancer patients, researchers have
sought alternative adjuvant treatment strategies. To assess the effects of fungi and other basidiomycetes Agaricales on
the co-adjuvant treatment of breast cancer, we conducted a literary review of the available scientific evidence. We
selected articles published in refereed journals from 1990 to 2011 in Medline, Lilacs, CAPES, Scielo, and Pubmed. Articles
written in English, Spanish, and Portuguese were reviewed. We used the following descriptors: Agaricales, medicinal
mushroom/fungus, breast cancer, dietary supplementation, synonyms, and related terms. The pharmacological effects of
nutritional and medicinal mushrooms have been reported in several experimental clinical studies and have shown
promising results in the adjuvant treatment of breast cancer. Adjuvant treatment with mushrooms is associated with
improvements in the immunological and hematologic parameters of breast cancer, as well as in the quality of life of
these patients. Randomized clinical studies are needed to elucidate the possible mechanisms of action and clinical
benefits of these fungi with respect to survival time, disease progression, and metastasis in breast cancer.
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INTRODUCTION
Breast cancer is highly prevalent in women. In 2008, the
IARC/OMS estimated that breast cancer was the second
biggest incidence of cancer in the world (1.29 million cases).
In Brazil, it would be responsible for 49,000 new cases in
women from 2010 to 2011 and the mortality rate for this type
of cancer remains high, on one side, due to the fact that this
disease continues to be diagnosed at advanced stages.1,2
Treatment for breast cancer is complex and varies accord-
ing to the histological diagnosis of the patient, the patient’s
age, the disease stage and the therapeutic approaches taken.3
Factors associated with tumor growth and the conventional
treatments used to treat cancer often result in malnutrition in
breast cancer patients. Side effects caused by conventional
treatments, significantly reduced caloric intake and decreased
absorption of nutrients can all complicate cancer treatment
and reduce the quality of life of cancer patients.4
Previous studies have sought to identify ways to improve
the quality of life and nutritional status of cancer patients
using adjuvant therapy with mushrooms.4-10
The most recent studies have shown that dietary
supplementation with Agaricales mushrooms and other
medicinal fungi in breast cancer patients can provide
benefits, such as antiproliferative and immunomodulatory
effects on tumor cells.11-15
The aim of this study is to analyze the effects of
mushrooms and other basidiomycetous Agaricales as adju-
vant treatments in breast cancer.
MATERIALS AND METHODS
A critical review of articles published in refereed journals
between January, 1990 to March, 2011 was performed.
Articles were identified in the Medline, Lilacs, Scielo, and
Pubmed, Health Science Descriptors (DeCS) and Medical
Subject Heading (MeSH) databases by searching for the
following terms: in English (Agaricales, Agaricus, medicinal
mushroom/fungus, breast cancer, dietary supplementation,
edible mushroom effects, lectin), in Portuguese (caˆncer de
mama, cogumelo medicinal), in Spanish (ca´ncer de mama,
suplementacio´n nutricional/diete´tica, cogumelos, hongos
medicinales).
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Table 1 - Mechanisms of action of various modulating substances present in mushrooms.
References Substances Benefits Mechanism of Action
Wang et al. (1996)
20
Lectin
Inhibits the growth of tumor cells
Two lectins (TML-1 and TML-2) were isolated from the mushroom
Tricholoma mongolicum. Both stimulated the production of
nitrite ions and activated macrophages in mice
Novaes et al. (2005a),5
Novaes et al. (2005b),6
Fortes & Novaes et al.
(2006),32 Fortes et al.
(2008),31 Fortes &
Novaes (2011)9
Cytotoxic activity against human tumor cells,
breast cancer and sarcoma 180 cells, inhibited
proliferation of mastocytoma cells in vitro and
sarcoma 180 cells in mice
Inhibits cell proliferation by blocking the import of
protein into the nucleus
Zhang et al. (2009)
17 Antiproliferative activity toward
hepatoma and breast cancer cells
Showed antiproliferative activity toward hepatoma Hep G2 cells
and breast cancer MCF7 cells with an IC(50) of 2.1 mM and
approximately 3.2 mM, respectively
Yang et al. (2009)
18 Tumor-suppressing function via apoptosis-
inducing activity in cancer cells
Dimerization of AAL is a prerequisite for tumor cell apoptosis-
inducing activity and requires galactose and glucose as basic
moieties of functional carbohydrate ligands for lectin bioactivity
Sendra et al. (2010)
16
Induces an immune response with tumor-
associated glycan specificity and biological
activity similar to that of ABL
Shows high-affinity binding to T antigen and reversible
noncytotoxic inhibitory effects on epithelial tumor cell
proliferation
Fujimiya et al. (1998)
21
b-Glucan
Tumoricidal activity
Directly inhibits tumor cell growth in vitro by inducing apoptotic
processing, increasing expression of the Apo2.7 antigen on the
mitochondrial membranes of tumor cells and selective cytotoxicity
toward tumor cells
Kodama et al. (2003)
22
Represses cancer progression, hinders
metastatic progress, lessens the expression
of tumor markers and increases NK cell
activity in all patients
Antitumor effect in tumor-bearing mice due to enhancement of
the immune system through the activation of macrophages, T
cells, and natural killer (NK) cells
Novaes et al. (2005a)5,
Novaes et al. (2005b),6
Fortes & Novaes
(2006),32 Fortes et al.
(2008),31 Fortes &
Novaes (2011)9
Enhances the immune system effects
Increases cellular and humoral immunity, the number and size of
the phagocytic cells, stimulates cytokine production by T cells and
increases the number of NK cells
Zhang et al. (2006)
24
Dose-dependently reduces proliferation and
viability of MCF-7 breast cancer cells (cancer-
cell growth was decreased by 50%)
Time-dependently induces cell cycle G1 arrest in approximately
90% of the cells by down-regulating the cyclin D1 and cyclin E
expression in MCF-7 breast cancer cells
Induces apoptosis through DNA alterations in subG1 cells
Induces depletion of the anti-apoptotic Bcl-2 protein
Demir et al. (2007)
23
Stimulates proliferation and activation of
peripheral blood monocytes in vivo in
patients with advanced breast cancer
Stimulates innate immunity by activating monocytes/
macrophages (CD95, CD45RA, CD14+)
Vetvicka et al. (2008)
45
Inhibits growth of tumor cells in vivo
and affects expression of several important
genes in breast cancer cells
Yeast-derived b-Glucan causes significant stimulation of
phagocytic activity as well as potentiation of synthesis and release
of interleukin (IL)-1, IL-2, IL-4, IL-6, IL-8, IL-13, and tumor necrosis
factor-alpha.
Jiang et al. (2010)
15
Inhibits cell proliferation and suppresses the
metastatic behavior of MDA-MB-231 breast
cancer cells
Inhibition of cell proliferation and cell cycle arrest at G2/M phase
in highly invasive MDA-MB-231 human breast cancer cells; linked
to the suppression of secretion of the urokinase plasminogen
activator (uPA) from these cells.
Inhibition of cell adhesion, cell migration and cell invasion
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Articles identified in the indexing databases mentioned
above, including both original articles and reviews of the
bioactive effects of edible mushrooms on cancer, were
selected for inclusion in this study. Experimental trials in
animals evaluating the efficacy of medicinal fungi treat-
ments in breast cancer and randomized clinical trials with
Agaricales mushrooms (and other medicinal fungi) in
humans with breast cancer were also included.
RESULTS AND DISCUSSION
Bioactive substances found in mushrooms and
other Agaricales medicinal fungi
The therapeutic effects of medicinal mushrooms are due
to the presence of lectin, b-glucan, ergosterol, arginine, and
other bioactive substances in mushrooms.5-9 The benefits
and possible mechanisms of action of these substances are
described in Table 1.
Lectins have been shown to be therapeutic agents with
anticancer properties in animals and in clinical studies. They
cause cytotoxicity and apoptosis and inhibition of tumor
growth by preferentially binding to cancer cell membranes.
Lectins function by sequestering the body’s polyamines,
thereby inhibiting cancer cell growth. Lectins also alter the
production of many interleukins, activate protein kinases,
bind to ribosomes, and inhibit protein synthesis. In addition,
lectins modify the cell cycle by inducing cell cycle arrest at the
G2/M phase, promoting apoptosis, and stimulating non-
apoptotic G1-phase accumulation mechanisms. Finally,
lectins can also down-regulate telomerase activity and inhibit
angiogenesis.16-20
b-glucan is a glucose polymer present in medicinal
mushrooms. It exhibits immunomodulatory effects as well
as tumoricidal and antiproliferative activities in cancer
patients through the stimulation of natural killer cells,
neutrophils, monocytes, macrophages, and T-cells.21-28
Ergosterol (or provitamin D2) is a precursor of ergocalci-
ferol, an important substrate in vitamin D biosynthesis and is
found in the lipid fraction of Agaricales extracts. This
substance has antitumor, antiproliferation, and antimigratory
effects on human cancer cells.25-27 It has also been shown to
inhibit angiogenesis. In a study on sarcoma 180 cells, patients
treated with ergosterol demonstrated delayed tumor growth
with minimal side effects. For example, the decrease in
lymphocyte count that is commonly caused by chemotherapy
was not observed in these patients. Ergosterol appears to
have no direct in vitro cytotoxic effects on tumor cells,
although it inhibits tumor-induced neovascularization.28
Arginine is a semi-essential amino acid used as a dietary
supplement in cancer patients. It has been associated with a
reduction of tumor growth and metastasis progression, and it
is reported to have beneficial effects on the immune system,
weight gain, and the time of survival of cancer patients.29,30
A complete understanding of the actions of these fungi
and their bioactive molecules in the prevention and
treatment of cancer will require further investigation.
However, research shows that many of these substances
exert anticarcinogenic, antiviral, antithrombotic, antibiotic,
References Substances Benefits Mechanism of Action
Takaku et al. (2001)
28
Ergosterol
Direct inhibition of angiogenesis induced
by solid tumors
Tumor growth was retarded by the oral administration of
the lipid fraction extracted from A. blazei in sarcoma
180-bearing mice.
Intraperitoneal and subcutaneous administration of ergosterol
inhibited the neovascularization induced by Lewis lung
carcinoma cell-packed chambers and Matrigel,
respectively, in female C57BL/6 mice.
Novaes et al. (2005a),5
Novaes et al. (2005b),6
Fortes & Novaes
(2006),32 Fortes et al.
(2008),31 Fortes &
Novaes (2011)9
Inhibition of tumor growth without causing
collateral damage
Inhibition of neovascularization induced by tumor growth
Wu et al. (2007)
26
Strong antitumor activity
Decrease of tumor size (60%) by cytotoxicity – exhibits a
significant inhibitory effect on B16-induced melanoma in C57BL/6
mice.
Lee et al. (2009)
27 Strong anti-migratory effect on human
cancer cells
Ergosterol peroxide and daucosterol inhibited the migration of
MDA-MB-231 cells.
Thohinung et al.
(2010)25
Anti-proliferation effect.
Cytotoxicity against the human breast cancer and
cholangiocarcinoma cell lines.
Novaes et al. (2005a),5
Novaes et al. (2005b),6
Fortes & Novaes
(2006),32 Fortes et al.
(2008),31 Fortes &
Novaes (2011)9 Arginine
Inhibits tumor growth, reduces nitrogen
losses and contributes to a positive
nitrogen balance
Increases the number of NK cells and T-helper lymphocytes,
stimulates the synthesis of cytokines, promotes the increase of
immunity through the release of growth hormone and produces
nitric oxide, hydroxyproline and polyamines
Zhang et al. (2011)
29
Anti-proliferation effect
Depletion of ARGLU1 significantly impairs the growth, as well as
anchorage-dependent and -independent colony formation of
breast cancer cells.
Tada et al. (2011)30 Improved anticancer activity
Mutated arginine on EGFR-lytic peptide produces higher binding
ability to EGFR on cancer cells.
Table 1 - Cont.
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and anti-inflammatory effects in addition to many other
activities that provide health benefits.5,6,9,31-32
Experimental studies with mushrooms and other
Agaricales medicinal fungi
Promising results have been reported in animals and in
vitro using medicinal mushrooms in the treatment of breast
cancer and several other cancers.33-49 Table 2 provides a
summary of the studies mentioned below.
Takimoto et al.33 demonstrated that rats administered
Agaricus blazei extract orally exhibited increased cytotoxic T
lymphocyte growth, increased levels of interferon-gamma and
an increase in NK cells when compared to water-treated
controls. This study indicates that mushroom extracts estimu-
late cytotoxic activity on both, innate and adaptive immuno-
logical systems.
Immunomodulatory, antitumor, and antiproliferative
effects of lectin isolated from various types of Agaricaceae
mushrooms have been demonstrated by Zhao et al.34 The
lectin contained in Agaricus bisporus has been shown to exhibit
an antiproliferative effect on breast cancer cells, and the lectin
contained in Tricholoma mongolicum has been shown to have
an inhibitory effect on mastocytoma cells (P815) in vitro.
In an in vivo study, extracts of Coriolus versicolor promoted
significant tumor reductions in mice inoculated with
mastocytoma tumor cells and mammary tumors.35
Chen et al.36 examined the ability of an Agaricus bisporus
extract to inhibit aromatase at the estrogen receptor in vitro
in MCF-7 cells and rat ovarian cells and in vivo in rats. The
extract inhibited cell proliferation. The linoleic and linolenic
acid present in the extract inhibited aromatase activity by
altering or mutating the active sites. The in vivo study
showed that the extract decreased proliferation and tumor
growth without affecting apoptosis in rats.
In studies of breast cancer cells (MFC-7), Grube et al.37
showed that Agaricus bisporus extract suppresses the activity
of aromatase, resulting in a reduction of estrogen produc-
tion, which is a major contributor to postmenopausal breast
cancer in women.
In experiments with breast cancer cells (MDA-MB-231),
Thyagarajan et al.38 showed that Ganoderma lucidum extract
inhibits cell proliferation and the formation of new cell
Table 2 - The effects of Agaricales mushrooms and other medicinal fungi on breast cancer: experimental studies in
animals, in vivo and in vitro.
References Mushroom Species Target Group/Tumor Results
Grube et al.
(2001)
37 Agaricus bisporus Breast cancer cells
Q aromatase enzyme activity, tumor cell proliferation and
estrogen production
Zhao et al.
(2003)34
Breast cancer cells (MCF-7) Q proliferation of tumor cells (via DNase)
Chen et al.
(2006)36
Breast cancer cells (MCF-7)
inoculated in mice
Q tumor cell proliferation and tumor growth
Talorete et al.
(2002)44
Agaricus blazei
Breast cancer cells
(MCF-7)
Q cell proliferation
Takimoto et al.
(2004)
33
Naı¨ve BALB/c and meth A-
bearing BALB/c mice
q natural killer activity of spleen cells in naı¨ve BALB/c
mice
Potentiated cytotoxic activity in innate and adaptive
immunity in meth A-bearing BALB/c mice
Chu et al.
(2002)
35 Coriolus versicolor
Mice inoculated with
mastocytoma cells and
mammary tumor
Q tumor cells growth
Jiang et al.
(2004)43
Ganoderma lucidum
Breast cancer cells
(MDA-MB-231)
Q tumor cell proliferation
Inhibited NF-kb messenger activity
Thyagarajan et al.
(2007)38
Breast cancer cells
(MDA-MB-231)
Q tumor growth and metastasis
Fang et al.
(2006)41
Lentinus edodes
Breast carcinoma cells
(MDA-MB-453 and MCF-7)
q antiproliferative activity
Israilides et al.
(2008)46
Breast carcinoma cells
(MCF-7)
Q tumor cell proliferation
q immune response
Sliva et al.
(2008)47 Phelinus linteus
Breast cancer cells
(MDA-MB-231)
Q tumor cell proliferation
Q angiogenesis
Jedinak et al.
(2008)42
Pleurotus ostreatus
Breast cancer cells
(MCF-7 and MDA-MB-231)
Suppressed tumor cell proliferation
Gu & Leonard
(2006)40
Several types of mushrooms
Several types of mushrooms
Breast cancer cells (MCF-7,
MDA-MB-231 and BT-20)
Inhibited tumor growth
Petrova et al.
(2007)39
Breast cancer cells
(MCF-7)
Inhibited messenger activity of NF-K b
Vetvicka et al.
(2008)45
Breast cancer cells Q tumor cell proliferation
Zhao et al.
(2003)34
Tricholoma mongolicum Mastocytoma cells (P815)
Inhibited tumor growth
(via apoptosis-inducing)
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colonies through the negative regulation of the expression of
c-myc, an oncogene. The combination of G. lucidum extract
with green tea extract demonstrated a synergistic effect by
suppressing secretion of urokinase plasminogen, which is a
breast cancer cell activator, and thereby suppressed the
growth and invasion of metastatic breast cancers.
In a study of breast cancer cells (MCF7), Petrova et al.39
noted that extracts of fungi significantly inhibited the
reporter activity of nuclear factor-kappa b (NF-kb) by
interfering negatively in its activation pathway. The study
was conducted with 28 fungi extracts, 40% of which were
found to inhibit NF-kb activity.
Gu & Leonard40 reported the activities of 38 species of
edible mushrooms in estrogen receptor-positive (MCF-7)
and negative (MDA-MB-231, BT-20) human breast cancer
cells. In aqueous extracts from Coprinellus sp., Flammulina
velutipes, and Coprinus comatus, anticancer agents were
identified that actively inhibited tumor growth.
Fang et al.41 conducted an in vitro investigation of
fractions of ethyl acetate extracts from Shiitake mushrooms
(Lentinus edodes) via biological assays of apoptosis and cell
cycle analysis in two human breast carcinoma cell lines
(MDA-MB-453 and MCF-7). The authors observed antipro-
liferative activity in all strains. Apoptosis was induced in
50% of the tumor cell lines via the positive regulation of bax,
a pro-apoptotic protein. Cell cycle analysis revealed a
decrease in the percentage of cells in S phase, an induction
of cdk inhibitors and p21 and a suppression of CDK4 and
cyclin D1 activities, thus indicating cell cycle arrest.
Studies using MCF-7 and MDA-MB-231 cells evaluated the
effectiveness of various types of edible mushroom extracts.
Jedinak & Sliva,42 using flow cytometry, revealed that
Pleorotus ostreatus inhibited the proliferation of these cells in
breast and colon cancers via p53-dependent and p53-
independent mechanisms. This fungus exerted its effect by
inducing the expression of the tumor suppressor p53 and the
cyclin-dependent kinase inhibitor p21 (CIP1/WAF1), but at
the same time inhibited the phosphorylation of retinoblas-
toma protein (Rb) in MCF-7 and HT-29 cells, breast and colon
cells respectively.42
A study by Jiang et al.43 revealed that Ganoderma lucidum
inhibits proliferation of MDA-MB-231 breast cancer cells. By
inhibiting Akt and NF-kappab activity in MDA-MB-231
cells, Ganoderma lucidum reduced their growth.
Talorete et al.44 isolated breast cancer cells (MCF-7) and
exposed them to an aqueous extract of Agaricus blazei. The
results indicated that this extract was able to reduce cell
proliferation in 26% compared to the control group, by
significantly enhancing the expression of an API gene
regulatory complex in the human breast cancer cell line
MCF7. This, again, highlights the anticarcinogenic potential
of mushrooms.
In a study of rats inoculated with breast cancer cells,
Vetvicka et al.45 observed a reduction in cell proliferation
after oral supplementation of b-Glucan extracted from
medicinal mushrooms. Likewise, a decrease in the prolif-
eration of cancer cells has been reported in studies carried
out by Israilides et al.46 with breast cancer cells (MCF-7) and
by Sliva et al.47 using the MDA-MB-231 cell line.
Clinical studies with breast cancer patients using
Agaricales mushrooms and other medicinal fungi
Although there are some inconsistencies in the results of
clinical studies regarding the use of medicinal mushrooms
as an adjuvant therapy in breast cancer treatment, the
majority of studies suggest a beneficial effect (Table 3).
A study in patients with breast cancer who received four
daily doses (1.6 g each) of Agaricus sylvaticus revealed that
Agaricus sylvaticus supplementation resulted in an increased
number of natural killer (NK) cells in 75.7% of the patients.
More than half of the patients were receiving chemotherapy
or radiotherapy, which typically reduces the numbers of NK
cells in the body.45,11
In a clinical study of various cancers, including breast
cancer (stage IV), Sliva et al.47 provided patients with a
complex of immunomodulatory components, including
Agaricus blazei tea (10 mg/day). After six months of
treatment, some patients had increased NK cell activity, as
well as increased levels of TNF-a (tumor necrosis factor),
Table 3 - The results of clinical studies using Agaricales and other medicinal fungi for dietary supplementation and
adjuvant treatment in patients with breast cancer.
References Mushroom Species Active Principle Target Group Results
Dolby (1997)12 Grifola frondosa D-fraction-b-Glucan and
total mushroom
15 women with breast
cancer
Q tumor size
improvement in clinical and biochemical
parameters
Q of vomiting and anorexia
Kodama et al. (2002)13 Grifola frondosa Mushroom powder Liver, lung and breast
cancer patients
increasing immune-competent cell activity
cancer regression or significant symptom
improvement
Gennari et al. (2002)48 Agaricus sylvaticus Mushroom Capsule 1 patient with breast
cancer and lung metastasis
q the number of NK cells and CD 56
total remission of lung metastasis
See et al.
(2002)49
Agaricus blazei Mushroom tea 5 stage VI breast cancer
patients
q the number of NK cells
stimulate macrophages and other
immunomodulatory effects
Hong et al.
(2008) 7
Several types of
mushroom
Mushroom total 362 women with breast
cancer in menopause
the consumption of dietary mushrooms may
decrease breast cancer risk in postmenopausal
women
Shin et al.
(2010)14
Several types of
mushroom
Mushroom total 358 women with breast
cancer
q mushroom consumption Q risk of breast
cancer in premenopausal women (stronger
with hormone receptor positive tumors)
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erythrocytes, hemoglobin, and glutathione. In contrast, the
number of TNF-a receptors was reduced. Diarrhea and
occasional nausea were reported, but the quality of life had
improved. The combination of immune-active components
was effective in increasing NK cell function and other
immunological parameters in patients with advanced stages
of cancer, thus providing an effective nutritional combina-
tion for the treatment of the late stages of cancer.47
Gennari et al.48 reported a case study of a patient with
breast cancer and showed that dietary supplementation with
Agaricus sylvaticus increased the number of CD56+ NK cells
in the blood and caused a total regression of lung metastasis.
Dolby12 reported that the D-fraction ob-D-Glucan (extracted
from Maitake) and mushroom tablets of Grifola frondosa had a
positive effect on the health status of the 15 breast cancer
patients included in the study. This study reported an
improvement in the clinical parameters and laboratory test
results of patients as well as improvements in their hemato-
logical parameters, reductions in the amount of vomiting
caused by chemotherapy, increased appetite and reduced
anorexia, which can be a side effect of conventional treatments.
Hong et al.7 conducted a study with 362 breast cancer
patients between 30 and 65 years of age. The frequency of
ingestion of mushrooms was measured through a specific
questionnaire. It was found that both the daily intake and
the frequency of consumption were inversely related to the
risk of breast cancer, especially in postmenopausal women.
Similar results were reported by Shin et al.14; however, in
the Shin study, the consumption of medicinal mushrooms
showed a strong protective effect against breast cancer in
premenopausal women as well.
Several published experimental clinical studies have
reported that medicinal mushrooms exhibit beneficial effects
on the health and quality of life in breast cancer patients. The
use of supplements as adjunctive therapies for the treatment of
breast cancer has shown promising results, such as antipro-
liferative effects on tumor cells and immunomodulatory
activities in the body. However, few articles have examined
the effects of supplementation with medicinal mushrooms for
the treatment of breast cancer. Therefore, new protocols for the
purpose of conducting clinical trials are required to elucidate
the possible mechanisms of action and clinical benefits of these
fungi with respect to the survival time, clinical progression
and quality of life of breast cancer patients.
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